ACE Inhibitors for Heart Failure: a Question of Dose

Overview

Journal Br Heart J

Specialty Cardiology & Vascular Diseases

Date 1994 Sep 1

PMID 7946796

Citations 4

Authors

J G Cleland

P A Poole-Wilson

Affiliations

Soon will be listed here.

Citing Articles

Clinical case studies in heart failure management.

MacFadyen R, Shiels P, Struthers A Br J Clin Pharmacol. 1999; 47(3):239-47.

PMID: 10215746 PMC: 2014219. DOI: 10.1046/j.1365-2125.1999.00882.x.

Optimal treatment of heart failure in the elderly.

Doughty R, Andersen V, Sharpe N Drugs Aging. 1997; 10(6):435-43.

PMID: 9205849 DOI: 10.2165/00002512-199710060-00004.

The renin-angiotensin system and cardiac remodelling after acute myocardial infarction.

Ikram H Heart. 1996; 76(3 Suppl 3):68-72.

PMID: 8983667 PMC: 484491. DOI: 10.1136/hrt.76.3_suppl_3.68.

Is aspirin safe for patients with heart failure?.

Cleland J, Bulpitt C, Falk R, Findlay I, Oakley C, Murray G Br Heart J. 1995; 74(3):215-9.

PMID: 7547012 PMC: 484008. DOI: 10.1136/hrt.74.3.215.

References

CALDWELL P, SEEGAL B, Hsu K, Das M, Soffer R . Angiotensin-converting enzyme: vascular endothelial localization. Science. 1976; 191(4231):1050-1. DOI: 10.1126/science.175444. View

Morgan K . Diverse factors influencing angiotensin metabolism during ACE inhibition: insights from molecular biology and genetic studies. Br Heart J. 1994; 72(3 Suppl):S3-10. PMC: 1025586. DOI: 10.1136/hrt.72.3_suppl.s3. View

Macgregor G, Markandu N, Roulston J, Jones J . Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme. Br Med J. 1979; 2(6198):1106-9. PMC: 1596971. DOI: 10.1136/bmj.2.6198.1106. View

Atkinson A, Morton J, Brown J, Davies D, Fraser R, Kelly P . Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition. Br Heart J. 1980; 44(3):290-6. PMC: 482400. DOI: 10.1136/hrt.44.3.290. View

Atkinson A, Cumming A, Brown J, Fraser R, Leckie B, Lever A . Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure. Br J Clin Pharmacol. 1982; 13(6):855-8. PMC: 1402024. DOI: 10.1111/j.1365-2125.1982.tb01878.x. View

Biollaz J, Schelling J, Jacot des Combes B, Brunner D, Desponds G, Brunner H . Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol. 1982; 14(3):363-8. PMC: 1427615. DOI: 10.1111/j.1365-2125.1982.tb01992.x. View

de Leeuw P, Hoogma R, van Soest G, Tchang P, Birkenhager W . Humoral and renal effects of MK-421 (enalapril) in hypertensive subjects. J Cardiovasc Pharmacol. 1983; 5(5):731-6. DOI: 10.1097/00005344-198309000-00005. View

Cody R, Covit A, Schaer G, LARAGH J . Estimation of angiotensin II receptor activity in chronic congestive heart failure. Am Heart J. 1984; 108(1):81-9. DOI: 10.1016/0002-8703(84)90548-9. View

Sharpe D, Murphy J, Coxon R, Hannan S . Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation. 1984; 70(2):271-8. DOI: 10.1161/01.cir.70.2.271. View

10.

Cleland J, Semple P, Hodsman P, Ball S, Ford I, Dargie H . Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure. Am J Med. 1984; 77(5):880-6. DOI: 10.1016/0002-9343(84)90530-8. View

11.

Cleland J, Dargie H, Hodsman G, Ball S, Robertson J, Morton J . Captopril in heart failure. A double blind controlled trial. Br Heart J. 1984; 52(5):530-5. PMC: 481676. DOI: 10.1136/hrt.52.5.530. View

12.

Franciosa J, Wilen M, Jordan R . Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure. J Am Coll Cardiol. 1985; 5(1):101-7. DOI: 10.1016/s0735-1097(85)80090-5. View

13.

Packer M, Medina N, Yushak M, Lee W . Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients. Br Heart J. 1985; 54(3):298-304. PMC: 481899. DOI: 10.1136/hrt.54.3.298. View

14.

Cleland J, Dargie H, Ball S, Gillen G, Hodsman G, Morton J . Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J. 1985; 54(3):305-12. PMC: 481900. DOI: 10.1136/hrt.54.3.305. View

15.

Packer M, Lee W, Yushak M, Medina N . Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med. 1986; 315(14):847-53. DOI: 10.1056/NEJM198610023151402. View

16.

Dzau V . Molecular and physiological aspects of tissue renin-angiotensin system: emphasis on cardiovascular control. J Hypertens Suppl. 1988; 6(3):S7-12. View

17.

Giles T, Katz R, Sullivan J, Wolfson P, Haugland M, Kirlin P . Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol. 1989; 13(6):1240-7. DOI: 10.1016/0735-1097(89)90294-5. View

18.

Linz W, Scholkens B, Ganten D . Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A. 1989; 11(7):1325-50. DOI: 10.3109/10641968909038172. View

19.

CHOBANIAN A, Haudenschild C, Nickerson C, Drago R . Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990; 15(3):327-31. DOI: 10.1161/01.hyp.15.3.327. View

20.

Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J . Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol. 1990; 15(2):276-82. DOI: 10.1097/00005344-199002000-00015. View